News: Gilead tops table for antivirals

StephenW

        Gilead tops table for antivirals        World News | January 26, 2012
        [url=http://www.pharmatimes.com/Article/12-01-26/href=%22http://www.addthis.com/bookmark.php?v=250&username=sarahbullard%22][/url]

       

        

        
Kevin Grogan     

   
            
With combined sales from the top HIV treatment on the market, Atripla, and several other drugs, Gilead Sciences leads the antiviral market, closely followed by Bristol-Myers Squibb, Roche and Merck & Co.
That is the key point in a report from Kalorama Information, the healthcare market research firm, which notes that the market for all anti-infectives reached $53 billion in 2011. It points out that Atripla (efavirenz/tenofovir/emtricitabine) is expected to bring in $3.2 billion in sales in 2011 and the HIV drugs Truvada (emtricitabine/tenofovir) and Viread (tenofovir), plus the hepatitis B drug Hepsera (adefovir) are performing well.
However, in a highly competitive market, other companies are gaining, the analysis notes. B-MS is second, driven by its nucleoside analogue Baraclude (entecavir) for hepatitis B; its sales have grown from $257 million in 2007 to $1.1 billion now. As for the firm's HIV drugs, the Sustiva (efavirenz) franchise and Reyataz (atazanavir) are growing steadily.
Roche holds the third market position overall, helped by Pegasys (peginterferon alfa-2a), for hepatitis B and C, the transplantation product Valcyte (valganciclovir) and the influenza jab Tamiflu (oseltamivir). At the end of last year, the Swiss major announced plans to acquire the USA's Anadys Pharmaceuticals, a hepatitis C specialist, for around $230 million.
Kalorama notes that GlaxoSmithKline alone accounted for 25% of the antiviral market in 2009, but has since declined due to patent expirations.  on key products. However its HIV joint venture with Pfizer, ViiV Healthcare, accounted for one-tenth of the antiviral drug market in 2011.

        
    Links            www.kaloramainformation.com

StephenW

从结合市场上顶端的艾滋病毒治疗，Atripla，和其他一些药物的销售，Gilead Sciences公司领导的抗病毒药物市场，紧接着由施贵宝，罗氏公司和默克制药公司
从卡洛拉马信息的报告，医疗保健市场研究公司，该公司指出，所有抗感染药市场在2011年达到530亿美元，这是关键点。它点出，Atripla（依非韦伦/替诺福韦/恩曲他滨）是预计到在32亿美元的销售额带来2011和的艾滋病毒药物Truvada（恩曲他滨/替诺福韦）和Viread（替诺福韦），加的肝炎乙药物Hepsera（阿德福韦酯）是执行以及。
然而，在激烈的市场竞争，其他公司获得，分析说明。 B - MS是第二，乙型肝炎的核苷类似物博路定（恩替卡韦）的带动下，其销售额2007年的257万美元增长到1.1亿美元。至于该公司的抗艾滋病毒药物，Sustiva（efavirenz的）的专营权和Reyataz（阿扎那韦）也在稳步增长。
罗氏公司拥有三分之一的市场地位，总体而言，派罗欣（聚乙二醇干扰素α-2a），乙型肝炎和丙型肝炎，移植产品Valcyte（缬更昔洛韦）和流感JAB达菲（奥司他韦）的帮助。在去年年底，瑞士主要宣布计划收购美国Anadys制药，丙型肝炎专科，为230亿美元左右。
卡洛拉马指出，葛兰素史克公司就占了在2009年的抗病毒药物市场的25％，但此后下降由于专利到期。重点产品。但其艾滋病毒与辉瑞公司，欢跃医疗，合资企业占抗病毒药物市场在2011年的十分之一。